Mereo BioPharma Group plc Banner Image

Mereo BioPharma Group plc has reached its limit for free report views

Work for Mereo BioPharma Group plc? Upgrade Your Profile and unlock all your annual reports.

Mereo BioPharma Group plc

  • Ticker MREO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mereo BioPharma Group plc Logo Image
  • 11-50 Employees
  • Based in London, England
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab ("Anti-TIGIT"), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b studyMore in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI"), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Mereo BioPharma Group plc

Most Recent Annual Report

Mereo BioPharma Group plc MOST RECENT 2019 Annual Report

Report Locked. Mereo BioPharma Group plc has reached its limit for free report views.

Older/Archived Annual Reports